Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 417,623,840
  • Shares Outstanding, K 1,768,169
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 24,061 M
  • 60-Month Beta 0.34
  • Price/Sales 6.76
  • Price/Cash Flow 15.44
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 29.11% (+1.72%)
  • Historical Volatility 25.53%
  • IV Percentile 80%
  • IV Rank 32.45%
  • IV High 51.27% on 04/08/25
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 1) 3.06 (1.33%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 8,416
  • Volume Avg (30-Day) 13,458
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 233,536
  • Open Int (30-Day) 227,899
  • Expected Range 226.58 to 232.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.01
  • Number of Estimates 10
  • High Estimate 3.17
  • Low Estimate 2.97
  • Prior Year 2.46
  • Growth Rate Est. (year over year) +22.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
218.05 +5.18%
on 02/11/26
237.11 -3.28%
on 03/04/26
+10.32 (+4.71%)
since 02/05/26
3-Month
204.27 +12.27%
on 02/04/26
237.11 -3.28%
on 03/04/26
+3.26 (+1.44%)
since 12/05/25
52-Week
164.39 +39.51%
on 04/09/25
244.81 -6.32%
on 10/01/25
+17.80 (+8.41%)
since 03/05/25

Most Recent Stories

More News
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration

ABBV : 230.20 (-2.54%)
AbbVie to Present at the Leerink Partners Global Healthcare Conference

NORTH CHICAGO, Ill. , March 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate...

ABBV : 230.20 (-2.54%)
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

NORTH CHICAGO, Ill. , March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating...

ABBV : 230.20 (-2.54%)
Is AbbVie Stock Underperforming the Dow?

Although AbbVie has lagged behind the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

$DOWI : 47,747.24 (-2.04%)
ABBV : 230.20 (-2.54%)
PFE : 26.57 (-0.19%)
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

NORTH CHICAGO, Ill. , Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate...

ABBV : 230.20 (-2.54%)
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

NORTH CHICAGO, Ill. , Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities...

ABBV : 230.20 (-2.54%)
1 Cash-Producing Stock to Target This Week and 2 We Ignore

1 Cash-Producing Stock to Target This Week and 2 We Ignore

VRNS : 23.54 (+0.21%)
DBX : 26.38 (+0.80%)
ABBV : 230.20 (-2.54%)
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

NORTH CHICAGO, Ill. , Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for...

ABBV : 230.20 (-2.54%)
AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill. , Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. 

ABBV : 230.20 (-2.54%)
1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

JPM : 294.38 (-1.67%)
ORCL : 152.97 (+0.39%)
ABBV : 230.20 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 243.21
2nd Resistance Point 240.16
1st Resistance Point 238.17
Last Price 230.20
1st Support Level 233.14
2nd Support Level 230.09
3rd Support Level 228.11

See More

52-Week High 244.81
Last Price 230.20
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar